The recently re-named pre-implantation genetic testing for determining embryo aneuploidies (PGT-A) is presently very popular although its acceptance by the scientific community is controversial. This approach still encounters drawbacks. This paper uses a SWOT (strengths, weaknesses, opportunities and threats) analysis to discuss salient points to be considered when examining the pre-implantation genetic testing (PGT-A) strategy to gather information from a range of perspectives. One of the strengths associated with the procedure is represented by an increase in implantation rate although data from the highest level of evidence do not support an increase in cumulative pregnancy rates. The current difficulty in the management of mosaicisms represents a weakness of PGT-A. The application of the strategy represents an opportunity to favor the single embryo transfer while other advantages, such as reduction of time to pregnancy and emotional distress are controversial. Potential important threats, at present still undefined, are represented by the biopsy-related damage to the blastocyst and the impact on neonatal and long-term outcomes. 1 Other randomized controlled trials (RCTs) confirmed that there was insufficient data to determine a beneficial effect of PGT-A applied on the live birth rate.
(FISH) actually reduced live birth rate in women with advanced maternal age (AMA) instead of improving it. 1 Other randomized controlled trials (RCTs) confirmed that there was insufficient data to determine a beneficial effect of PGT-A applied on the live birth rate. 1, 2 On this basis, newer genetic technologies have been developed to achieve the 24-chromosome screening, allowing the assessment of the whole chromosome complement. Moreover, the trophectoderm (TE) biopsy of day 5/6 blastocyst stage embryos has become the common practice based on evidence showing that implantation potential of the biopsied embryos would not be affected if the biopsies are taken at blastocyst stage. 3 Notwithstanding these improvements referred as pre-implantation screening version 2.0, whether PGT-A should be offered routinely to in vitro fertilization (IVF) patients is still at the heart of the debate.
This review uses a SWOT (strengths, weaknesses, opportunities and threats) analysis to identify and discuss salient points to be considered when examining the PGT-A strategy. This tool represents a means of gathering information from a range of perspectives. The outcome shows the strengths of PGT-A while also helping to identify the major urgent needs. More specifically, the analysis underlies the dichotomy between the existing gaps in the current literature on PGT-A and the accelerated uptake of the procedure in clinical care.
| STRENGTHS
In general, novel strategies procedures aiming at enhancing fertility should be introduced in clinical practice with well-designed and conducted randomized controlled trials (RCTs). Non-randomized studies tend to show larger treatment effects than RCTs. 4 Improvement in research methodology limits biasing factors that inflate effects as supported by the progressive reduction of effect sizes over time as the quality of studies on gynecological procedures ameliorated. 5 Producing robust data on assisted reproduction innovation seems feasible.
| Prospective RCTs: implantation and pregnancy rates
Three RCTs have evaluated the performance of the new version of PGT-A with the biopsy at the blastocyst stage associated with comprehensive chromosome screening (CCS) in good prognosis patients (Table 1) . [6] [7] [8] In the first RCT, patients with a good prognosis (age <35, no previous miscarriage, tubal or male factor infertility and no prior IVF cycle) and normal karyotype undergoing a single embryo transfer (SET), were prospectively randomized. In one group, blastocysts were selected on the basis of both morphology and CCS by array comparative genomic hybridization (aCGH) and in the other group, blastocysts
were morphologically assessed only. Although no power calculation was provided, a significantly higher implantation rate and significantly increased clinical and ongoing pregnancy rates per randomized patient were found in the PGT-A group. 6 In the second RCT, good prognosis patients (≤42 years, AMH ≥ 1.2 ng/mL, day 3 FSH <12 IU/L) were randomized when at least two blastocysts were available for biopsy. Patients underwent a single euploid blastocyst transfer after PGT-A using quantitative PCR (qPCR) or a transfer of two untested blastocysts, whether fresh or frozen. A similar ongoing pregnancy rate per randomized patient was observed between the two groups. However, a positive trend toward a higher implantation rate (P = 0.08) after a single euploid blastocyst transfer was found. 7 The risk of multiple pregnancy was reduced sharply in the PGT-A group. 7 In the third RCT, Scott et al 8 randomized infertile women (maternal age 32.2 ± 0.5 in PGT-A group vs 32.4 ± 0.5 in control group) with no more than one previous failed IVF cycle, with a basal follicle count of eight or more and basal FSH ≤ 15 IU/L. Significantly higher delivery rate per cycle and implantation rate resulted in the PGT-A group using qPCR, compared to the untreated group. The study design considered a maximum of two euploid embryos for transfer but 10 patients had only a single euploid blastocyst, resulting in a statistically significant difference in the number of blastocysts transferred in the study group compared to the control group (1.8 ± 0.04 vs 2 ± 0.00; P < 0.0001).
8
Two meta-analyses have analyzed overall data from RCTs. Pooled analysis showed a significant increase in implantation rate while no difference was observed for clinical, ongoing pregnancy and miscarriage rates. 9 Dahdouh et al 10 confirmed that PGT-A was associated with an increase of clinical and sustained implantation rates. Analysis of other outcomes has not been performed 10 ( Figure 1 ). On the other hand, the main cause of infertility is AMA, which is associated with a decrease in ovarian reserve, impairment of oocyte quality and increased embryo aneuploidy, resulting in implantation failure and miscarriage. 11 The incidence of chromosome abnormalities varies from about 40% in fertile egg donors to 80% in patients 41 to 42 years old. 12 The literature presents only one RCT in women aged 38 to 40 using CCS applied on day 3 embryos. 13 This study confirmed the same results obtained in the good prognosis population also in AMA patients showing an increase in implantation rate using PGT-A. Moreover, the delivery rate after the first transfer attempt was significantly increased in the PGT-A group both per transfer and per cycle (Table 1) . 13 
| Miscarriage rate
To transfer a single euploid blastocyst might represent an optimal strategy to reduce pregnancy loss and potential live births with chromosomal abnormalities. In young and good prognosis patients, a decreased but not significant miscarriage rate was observed in the PGT-A group compared to controls, a result also confirmed by a metaanalysis. 6, 7, 9 Only the RCT on AMA patients showed that PGT-A was associated with a significantly lower miscarriage rate (2.7% vs 39.0%, P = 0.0007) (Figure 1 Although the authors claimed that PGT-A increased implantation and delivery rates, there was a fundamental methodological flaw in the study that failed to account for the difference between the unit of randomization (patients) and the unit of analysis (individual embryos).
Forman et al 7 included 89 good prognosis patients and the RCT suffered of the same methodological problem encountered in the trial by Scott et al. 8 Concerning CCS technology, the aCGH was used in one study 6 while qPCR was applied in the other two. 7, 8 Next-generation sequencing (NGS) technology is presently subverting these techniques. 15 Moreover, in two RCTs, the interpretation of the implantation rate was difficult as in one, a single euploid blastocyst vs two untested blastocysts were transferred 7 while in the other, two fresh blastocysts were transferred in both arms, except for 10 patients in the PGT-A group with only one euploid embryo to transfer. 8 Finally, the implantation rate should be abandoned as main outcome for clinical trials essentially for two reasons. First, women are interested in having babies and not implantations; the implantation rate represents a surrogate outcome to show the effectiveness of a treatment for our patients. Second, in randomized studies involving PGT-A, based on the embryo selection so that fewer embryos were classified as trans- Strengths, weaknesses, opportunities and threats analysis of the preimplantation genetic testing for aneuploidies strategy the study group. Consequently, the implantation rate resulted significantly higher in the study group only as a consequence of the higher number of embryos transferred in the control group (Figure 1) . 16 
| Cumulative IVF outcomes
With advances in embryo cryopreservation, the real success of an IVF cycle is represented by the cumulative live birth rate that incorporates fresh and thawed frozen embryo transfer. 17, 18 For every "add-on" intervention introduced in the IVF clinical practice, an improving of the cumulative chance of a live birth would be advisable. 17 According to the single RCT study that has addressed this outcome, the cumulative IVF success was not improved. However, this study was performed using day 3 embryos (Figure 1 ). 13 26 Even so, depending on the depth of sequencing and the specific NGS platform used, the sensitivity for detecting cytogenetically distinct subpopulations of cells varies as NGS strategies change.
Unfortunately, NGS cannot directly detect balanced chromosomal rearrangements, because there is no imbalance in the total DNA content. 24 Because of differences in protocols and methodologies, current data do not exist to irrefutably determine the superiority of any platform to the others (Figure 1 ).
| Management of mosaicisms
Management of mosaicisms represents a critical issue for PGT-A. The primary origins of embryonic mosaicisms are the post-zygotic chromosome segregation errors because of mitotic non-disjunction, anaphase lag, chromosome deletion or duplication. 27 An embryonic mosaicism might also be induced by IVF treatments such as the ovarian stimulation and/or in vitro culture of human embryos. Indeed, the type of ovarian stimulation may influence the rate of chromosomal mosaicisms. 28 In mouse models, changes in oxygen tension during embryo culture have been shown to affect chromosomal mosaicism rates. 29 Recently, the incidence of chromosome abnormalities in human embryos has been shown to be fertility center-dependent, indicating that mosaicism rate could very probably be influenced by culture conditions as temperature, pH and media composition. The possibility to detect chromosomal mosaicisms in embryos has given rise to novel clinical challenges in PGT-A result interpretation and patients' counseling. At the introduction of PGT-A, only euploid embryos had been considered for transfer while mosaic embryos were not transferred being considered as abnormal. Recent studies showed that mosaic blastocysts miscarry more often and implant less frequently than an euploid blastocyst but a proportion of mosaic embryos can implant and result in healthy babies. 41, 44, 45 In a chimeric murine model, mosaic embryos have been shown to undergo a "selfcorrecting" mechanism if they contain sufficient euploid cells. 46 Taking 47 Moreover, the same guidelines recommended to PGT-A laboratories the use of NGS, which is capable of measuring chromosomal copy numbers, as the only diagnostic platform adequate in assessing TE mosaicism. 47 In support to the PGDIS position statement, at the 2016 World Congress on Controversies in Pre-conception, Pre-implantation, Prenatal Genetic Diagnosis (CoGEN) Meeting, a group of investigators reached similar conclusions, advising to prioritize transfer of mosaic embryos with lower levels (20%-40%) of aneuploidy over those with higher levels (40%-70%), and defining any embryo TE biopsy with more than 70% aneuploidy as aneuploid and, consequently, not to be transferred. 48 In contrast to PGSIS position statement, CoGEN Consensus statement considered embryos mosaics for monosomies with similar implantation rate to mosaic trisomies because mosaic monosomies might contain trisomic cell lines, enabling them to implant. 48 The chance of a healthy live birth seems to vary depending on the rate of mosaicism and on the type of aneuploidy. In fact, according to the group of Spinella et al, 49 embryos with a high chromosomal mosaicism (≥50%) showed a significant reduction in terms of implantation and live birth rates, compared with mosaic embryos with a lower aneuploidy percentage (<50%). Furthermore, blastocysts with lower levels of mosaicism (<50%) were associated with outcomes similar to euploid embryos. Miscarriage rates did not seem significantly different. 49 These findings are in contrast with those from Kushnir et al 50 that reanalyzing the raw data reported from Munnè et al 45 to assess accuracy of the mosaicism percentage in predicting ongoing pregnancy and miscarriage rates, found that the degree of TE mosaicism, at any threshold of aneuploidy, was a poor predictor for both IVF outcomes. Given the financial and emotional impact of failed IVF cycles on patients, research to delineate the characteristics of mosaicisms potentially compatible with healthy live births is urgently needed (Figure 1 ).
| OPPORTUNITIES

| Single embryo transfer policy
Multiple pregnancies carry adverse outcomes such as an increased risk of premature birth and perinatal death. 51 To reduce the rate of multiple births, a limitation on the number of transferred embryos has been recommended, especially, in good prognosis patients. 52 The eSET is the most obvious way of avoiding the risk of twins following IVF cycles. The uptake of this strategy has been variable, and it is mandatory only in some countries. 53 In this context, the application of the PGT-A strategy represents an opportunity to select embryos to transfer ( Figure 1) . Importantly, the eSET does not impact negatively on the cumulative live birth rates. A Cochrane study showed no evidence for a significant difference in the cumulative live birth rate when a single cycle of double embryo transfer was compared with repeated eSETs. 54 According to Ubaldi et al, 55 the application of eSET in combination with the appropriate selection of blastocysts by PGT-A could be considered an efficient approach also in AMA patient. Indeed, after the introduction of an eSET policy coupled with PGT-A, multiple pregnancy rate decreased from 21.0% to 6.8%, maintaining constant the cumulative success rate of the IVF program.
| Time to pregnancy
Couples undergoing several IVF failures or miscarriages may undergo economic and psychological burdens. Moreover, pregnancy represents a race against time for women older than 35 years. If PGT-A is performed, the couple may conceive a healthy baby in a shorter time transferring only euploid embryos, and this might be an advantage mainly for AMA patients. According to the RCT by Rubio et al, 13 the time for a successful ongoing pregnancy was reduced, but not significantly, in patients undergoing PGT-A. Recently, a retrospective cohort study involving AMA women showed that the PGT-A group achieved a clinical pregnancy leading to a live birth in a shorter time, compared to controls (104.8 days vs 140.6 days, P < 0.05). 56 Nowadays, this is the only study that supports PGT-A procedure as a good strategy to obtain a clinical pregnancy in a shorter time. Nevertheless, the value of this data was strongly limited by the retrospective nature of the study (Figure 1) . A shorter time to obtain a pregnancy entails a reduction in the number of embryo transfers with a consequent reduction in costs.
| Psychological aspect of health care
An indication to PGT-A treatment might be represented by repeated miscarriages and recurrent implantation failures on the basis of the idea that the consequent psychological sequelae often involve grief, guilt, loss and, in some cases, psychiatric disturbances including depression, anxiety and post-traumatic stress disorder. 57 In addition, unresolved grief, interpreted as parents who continue to grieve the loss of the previous baby rather than happily anticipating a baby in a new current pregnancy, can impact on attachment to subsequent pregnancies. 58 Therefore, on the basis of the supposed opportunity to reduce the time to pregnancy, PGT-A is often offered to reduce the emotional distress of multiple embryo transfers with negative outcomes. Moreover, the cryopreservation of embryos with a real poten- Results would indicate that cost increases in poor prognosis patients. 63 More research on this aspect is needed, considering the potential advantage of NGS in reducing costs by high throughput sequencing technologies and the increasing number of samples that can be simultaneously sequenced during a single experiment. Alternatively to blastocyst biopsy, less-invasive techniques are being developed. Many studies focused on cell-free DNA recovered from blastocoel fluid with controversial data regarding the concordance rate with TE cells. [66] [67] [68] [69] Recently, cell-free DNA has also been detected in blastocyst-spent culture media but no agreement on concordance rate with the genetic status of embryos has been found. [70] [71] [72] [73] [74] Although both strategies appear to be attractive methods, they are characterized by some limitations including the incomplete representation of the whole embryonic genome, the potential maternal DNA contamination, the poor nucleic acid integrity and the unknown sampling time points to obtain acceptable amplification rates. 75 Well-designed studies are needed to evaluate the efficacy of cell-free DNA employment on clinical outcomes.
| Obstetrical and perinatal outcomes
Reports on neonatal outcomes and obstetrical complications of PGT pregnancies are limited. [76] [77] [78] [79] [80] [81] [82] Some studies have evaluated the effects of embryo biopsy without distinction between PGT-M and PGT-A. 77, 80 It is necessary to consider that the technical procedures for PGT-M and PGT-A are similar, while the indication for these techniques is not. Indeed, PGT-M is applied in fertile couples, whereas PGT-A is used in infertile couples undergoing IVF. As infertility condition is associated with obstetrical complications, perinatal adversities and a less optimal neurological development, PGT-A children could be at higher risk for adverse outcomes compared to PGD offspring. 83 Only an RCT and a retrospective questionnaire analysis have analyzed obstetrical and neonatal outcomes in patients who underwent PGT-A only (Figure 1) . 82, 84 Forman et al 84 showed that single euploid blastocyst transfer had significantly better obstetrical outcomes than double untested embryo transfer. A lower birth weight and a longer period spent in the neonatal intensive care unit have been reported for untested newborns but the consequences of multiple pregnancies in this group represent an obvious explanation. Jing et al 82 found a higher incidence of gestational hypertension in singleton pregnancies after blastocyst stage biopsy and frozen embryo transfer than after cleavage stage biopsy and fresh embryo transfer. In the present study, vitrification may be an important factor for the high incidence of gestational hypertension.
| Long-term outcomes
The relative invasiveness of the embryo biopsy inherent to PGT-A raised issues on its safety on children development. Currently, data on developmental status and health of PGT-A offspring is scarce ( Figure 1 ). From the paper by Mastenbroek et al, 1 six prospective, assessor-blinded follow-up studies were derived on children born to women undergone PGT-A or not, to evaluate neurodevelopmental outcomes at 18 months, 2, 4 and 9 years. [85] [86] [87] [88] [89] [90] In these studies, no statistically significant differences in mental, psychomotor, neurological and behavioral outcomes were reported between children born after PGT-A and those born without PGT-A. Unfortunately, the power calculation of the original RCT was based on the number of women needed to detect an increase in ongoing pregnancy rates and not on the number of children to be followed-up. Nevertheless, in two of these studies, according to the post-hoc power analysis, the sample size seemed to be able to detect clinically relevant differences. 88, 90 None of the studies has addressed the long-term follow-up of children born after PGT-A at the blastocyst stage.
| CONCLUSIONS
Various SWOT analyses have been delineated in the last years for novel strategies that are entering dramatically in the clinical practice in the IVF world. [91] [92] [93] Although the major advantage of the PGT-A procedure is the selection of the embryo to transfer to favor the eSET and reduce the number of transfers, several other factors such as the potential reduction in miscarriage rate, also support a move toward this approach in assisted reproduction technology (ART). The psychological burden and the reduction in costs in a wider perspective than so far investigated are elements that should be better investigated. Taken together, these developments may lead to a new era in modern ART. Nevertheless, confirmation that risks and threats associated with this strategy do not overcome benefits and opportunities is mandatory prior to shifting our current practice toward the routine use of blastocyst biopsy with genetic testing in all infertile patients.
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